trending Market Intelligence /marketintelligence/en/news-insights/trending/eya3ejbrorvbsq3spbrq4g2 content esgSubNav
In This List

Advaxis seeks to raise $20M from common stock, warrants offering

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Advaxis seeks to raise $20M from common stock, warrants offering

Advaxis Inc. expects to raise gross proceeds of about $20 million from its underwritten public offering of 16,666,666 common shares and warrants to purchase 14,166,666 shares.

Each common share is being sold together in a fixed combination with a warrant to purchase 0.85 common share.

Holders can immediately exercise warrants at $1.50 per share, subject to anti-dilution adjustments. The warrants will expire six years after issuance.

The Princeton, N.J.-based biotechnology company plans to use the funds from the offering for the development of its product pipeline, which includes the experimental cancer treatment ADXS-HOT.

The offering is expected to close Sept. 11, subject to customary closing conditions.

Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc. are acting as joint book-running managers for the offering.